NEW YORK — ADx NeuroSciences and Alamar Biosciences said Monday that they have partnered on the development of customized blood-based assays for clinical biomarker analysis.
Under the terms of the deal, the companies will use Alamar's NULISA immunoassay platform and Argo HT automated proteomics system to build tools for the detection and quantification of biomarkers that can be used for neurological disease drug development.
Financial and other terms were not disclosed.
"By combining our NULISA platform's ultra-sensitive detection capabilities with ADx's extensive expertise in neuroscience antibody and assay development, we aim to accelerate the development of biomarker assays that can facilitate the development and approval of disease-modifying therapies for neurodegenerative diseases," Alamar Chairman and CEO Yuling Luo said in a statement.
Based in Ghent, Belgium, ADx is a subsidiary of Japan's Fujirebio.
Alamar is currently involved in patent infringement litigation over the NULISA technology. The Fremont, California-based firm recently highlighted the interest it has received from Alzheimer's disease researchers.